StockWatch
·
HomeLiveReports

HESTER BIOSCIENCES LTD. Q1 FY27 Results

HESTERBIOQ1 FY27 Results
Filing
Result:Weak· Market: FlatOne-off gainBase effect

Outlook: Optimistic · Guidance: Maintained

MetricValueQ4 FY26Q1 FY26
Revenue77.24 Cr22.8%8.2%
Total Income78.89 Cr18.7%8.7%
Expenditure64.59 Cr15.9%4.0%
PBT99.64 Cr328.9%420.7%
Net Profit96.73 Cr484.6%459.3%
OPM100.00%62.77pp72.87pp
NPM100.00%82.96pp79.99pp
EPS113.71484.6%459.3%
View full financials

Adjusted PAT (stripping the one-off Gates Foundation loan-restructuring gain) fell ~34% YoY and consolidated revenue fell 8% YoY, with Animal Healthcare swinging to a loss, so the core Pharma/Biotech result is a below-par decline masked by a non-operating gain.

HESTER BIOSCIENCES · Q1 FY-2027 · THE VERDICT

Poultry Fires, but the Quarter's Profit Hinges on Gates Foundation

Reported net profit surged 459% to ₹96.7 Cr, but a ₹7 million USD exceptional gain from a Gates Foundation debt waiver masks a much weaker underlying operational picture. Poultry growth is genuine and strong; the rest of the story is decidedly less so.

02 Aug 2026 · 6 min read
Reported PAT

₹96.7 Cr

+459% YoY

Exceptional gain (Gates Foundation)

~₹55–60 Cr est.

USD 7M+ debt waiver

Adjusted PAT (est.)

~₹36–42 Cr

Organic operational profit

Consolidated Revenue

₹77.2 Cr

-8.2% YoY

The Quarter in One Sentence

Poultry division delivered a genuine 48% YoY surge (₹60+ Cr, up from ~₹45–48 Cr), driven by market penetration and traction from the newly approved LPAI vaccine and companion products like biosecurity aids and feed supplements. But consolidated revenue declined 8.2% YoY to ₹77.2 Cr — a ₹20+ Cr drag from international weakness (Nepal, Africa) that management's guiding narrative of 'balanced 50/50 revenue mix' has failed to deliver. And the reported ₹96.7 Cr net profit, which appears to be a blowout, is almost entirely a one-time exceptional gain: a ₹55–60 Crore (USD 7 million) accounting entry from the Gates Foundation restructuring Hester Africa's debt (reducing USD 12 million to USD 5 million and waiving interest). Strip that out, and underlying profit collapses to roughly ₹36–42 Crore — still respectable, but a far cry from the 459% headline.

Where the Reported Profit Came From

The company reported a 100% net profit margin (₹96.7 Cr PAT on ₹77.2 Cr revenue). This is impossible on operations alone. Management disclosed: 'Consolidated profitability during the quarter includes an exceptional accounting gain arising from the amendment of the soft loan extended to Hester Africa by the Gates Foundation.' The gain: USD 12 million debt reduced to USD 5 million, interest waived going forward. That's a ₹55–60 Crore non-cash benefit in a single quarter, accounting for ~60% of reported PAT. Without it, the quarter is operationally weak — consolidated revenue down, Animal Healthcare delayed, and international operations still loss-making.

Q1 FY-2027 PAT, ₹ Cr
036.172.2108.396.7Reported PAT55Exceptional gain41.7Adjusted PAT (est.)
Exceptional gain from Gates Foundation debt waiver is ~58% of reported profit. The organic operational number is significantly lower.

Management's Claims vs. What Holds Up

Grading management's on-call assertions against delivered results and guidance track record

Consolidated revenue decline driven by Nepal, Africa weaker performance

Consolidated -8.2% YoY (₹77.2 Cr vs ~₹84.1 Cr prior). Standalone +14% shows large (~₹20 Cr) international drag offsetting domestic strength.

Supported

Gross margins improved 69% to 78%

Gross margin improvement on standalone basis confirmed. But consolidated 100% NPM is an artifact of the exceptional gain, not operations.

Overstated (margin quality)

Poultry Healthcare grew 48% YoY with new products contributing

~₹60+ Cr vs ~₹45–48 Cr prior = 25–33% sequential; 48% YoY growth aligns with new products (LPAI vaccine, feed supplements, disinfectants) and market penetration.

Supported

Animal Healthcare impacted by government tender timing; recovery expected

Prior call (Q4 FY-26) promised 'recovery starting in upcoming quarter.' Q1 shows continued delays: 'pending PPR eradication, Lumpy Skin Disease programs.' Expectation unmet.

Contradicted

PAT increased 88% on standalone basis

Standalone PAT growth 88% is plausible given margin expansion and poultry growth. But consolidated 459% is almost entirely the Gates Foundation exceptional gain, not operations.

Overstated (in aggregate)

What Changed on This Call

Upgrades and Downgrades

  • Upgrade: Poultry accelerating faster than the guided 50/50 mix target. Market penetration and new products (LPAI, feed supplements) outpacing expectations.

  • Downgrade: Animal Healthcare tender recovery promised in Q1; delays persist. No material progress vs. prior guidance.

  • Downgrade: Consolidated revenue decline broader than strategic narrative implied. International (Nepal, Africa) drag ~₹20 Cr YoY, a larger headwind than modeled.

  • New: Gates Foundation restructured Hester Africa debt (USD 12M → 5M, waived interest). Reflects geopolitical and operating challenges in Africa; profitability unviable without subsidy.

The Bull-Bear Ledger

  • Bull: Poultry division posting genuine 48% YoY growth, driven by market share gains and new products (LPAI vaccine approved March 2026, early market traction confirmed). Capacity still 60–65% utilized; room to grow without new capex.

  • Bull: Operational margin expansion on standalone basis (gross margin 69% → 78%, EBITDA +95% YoY). Shows unit economics improving.

  • Bull: Management invested in R&D pipeline (Brucella recombinant vaccine in progress, new poultry health products—biosecurity, gut health—gaining traction). Structural diversification underway.

  • Bear: Consolidated revenue declined 8.2% YoY despite domestic poultry momentum. International (Nepal, Africa) drag is structural and persistent; no clear path to profitability without debt relief.

  • Bear: Animal Healthcare recovery guidance from prior call missed. Tenders delayed; management reframed as 'timing' not 'structural,' but pattern of quarter-to-quarter delays continues.

  • Bear: Reported ₹96.7 Cr PAT is almost entirely an exceptional gain (Gates Foundation). Underlying operational profit ~₹36–42 Cr; real profitability deteriorates materially once one-time is excluded.

  • Bear: Management refuses all near-term guidance (revenue, margin, timelines). Non-committal on Africa profitability ('formative period,' 'will happen in time'). Credibility on near-term execution is low.

  • Bear: Cash conversion concern raised by analyst on call; management dismissed as 'seasonal receivables.' Issue not fully resolved.

Risks, Ranked by How Much They Should Concern a Holder

Material risks ordered by severity and impact to equity value

Earnings quality: Exceptional gain masks weak operational profitability

High

₹96.7 Cr PAT is 60% exceptional gain; adjusted profit ~₹36–42 Cr. Consolidated revenue down 8.2% YoY. Real operational margin is much lower than reported 100% NPM, and declining. Investors overpaying for headline PAT that is non-recurring.

Government tender volatility (Animal Healthcare)

High

Animal Healthcare is ~40–50% of revenue, entirely dependent on government PPR and Lumpy Skin Disease program cycles. Q1 guidance miss shows quarter-to-quarter delays are recurring. Management claims 'steady over 1–3 years,' but near-term swings material.

International profitability unresolved (Africa, Nepal)

High

Hester Africa and Nepal are loss-making; without Gates Foundation debt relief this quarter, Africa's profitability deteriorates further. No timeline given for when these regions turn cash-positive. Long-term 'formative period' language suggests multi-year struggle.

Management credibility on near-term guidance

Medium

Prior call promised Animal Healthcare recovery in Q1; missed. On this call, management refused directional guidance 5+ times and blamed externals (government timing, geopolitical). Pattern of deferring expectations erodes trust in near-term forecasting.

Cash conversion / working capital

Low

Analyst pressed on weak operating cash flow vs. reported profit; management dismissed as 'seasonal receivables.' Issue not fully resolved but CFO acknowledged 'improved.' Monitor for deterioration in receivable days and cash flow.

How the Street Is Positioned

The market's reaction on day 1 was a modest -1.06% decline (from ₹2,478.2 pre-result to ₹2,452), with 53.5% delivery suggesting some rotation out of speculative positions. The stock now trades at ₹2,452, sitting comfortably above all three major moving averages (SMA20 ₹2,375, SMA50 ₹2,180, SMA200 ₹1,720), signaling a structurally bullish trend. However, it is 8.22% below its all-time high of ₹2,671.6, suggesting the market has already discounted near-term disappointment. RSI at 43.7 (neutral) shows neither overbought nor oversold conditions — room to move either direction depending on next quarter's execution.

Ownership flows are headwinds. FII holdings have shrunk to 0.38% (latest), down from 0.87% a year ago — a 49 bps decline — and -13 bps quarter-on-quarter. This suggests foreign institutional capital has been trimming exposure over the past year, even as the stock rallied 96% off its 52-week low. DII holdings are negligible at 0.01%, signaling domestic institutions are also not aggressively backing the story. Promoter ownership remains steady at 53.73%, showing no insider selling but also no buying conviction near the all-time highs. The combination — falling FII, low DII, steady promoter, and modest post-result price decline — reads as the market digesting the earnings and finding the stock fairly valued to slightly expensive on an organic basis.

The day-1 price action and the FII trimming align with the fundamental story: headline PAT growth of 459% is a mirage (exceptional gain). Organic growth is much weaker, and international drag persists. The market is not yet punishing the stock sharply, but the absence of buying (especially from FII) suggests skepticism about near-term catalysts. The next quarter's cash flow and Animal Healthcare tender progress will be make-or-break for investor confidence.

The Debate

What to Watch Next

Three Concrete Metrics to Resolve the Debate

  • 1 · Q2 Consolidated Revenue and Segment Mix

    Will consolidated revenue return to growth, or does international drag persist? Watch the poultry growth rate (Q1: 48% YoY) and Animal Healthcare recovery (tenders released or delayed again?). If consolidated revenue stays negative YoY and Animal Healthcare remains impaired, the international drag is structural, not timing.

  • 2 · Adjusted PAT and Operating Cash Flow

    Exclude any exceptional gains from Q2 PAT and see the organic run-rate. Also monitor operating cash conversion — the analyst's concern about weak OCF vs. reported profit needs resolution. If receivables remain elevated and cash flow lags, there's a working capital problem beneath the profit line.

  • 3 · Animal Healthcare Tender Wins and Timeline to Recovery

    Management promised recovery this quarter; it didn't materialize. By Q2 earnings, ask: Did PPR eradication or Lumpy Skin Disease programs release? Any concrete tender wins announced? If tenders are still 'pending' and recovery deferred to Q3, credibility erodes further and the guidance miss becomes a pattern.

The Number to Track

From here, the key metric is adjusted consolidated PAT (net of any exceptional gains). Reported profit is a distraction; organic profit is the truth. If Q2 adjusted PAT comes in at ₹35–40 Cr (low-to-mid 30s range), the company is treading water despite Poultry growth. If it rebounds to ₹45+ Cr, management has a real story. Paired with that: consolidated revenue growth. If revenue is still negative YoY in Q2, the international headwind is not timing, it's structural, and the 50/50 mix goal is a fantasy. Close the quarter watching these two numbers; everything else is narrative.

Hester Biosciences is a steady operator with a genuine growth engine in Poultry and promising R&D optionality. But this quarter reads as a company in transition — profitability is being propped up by one-time gains while the core business treads water on a consolidated basis. Animal Healthcare is stuck, international expansion is bleeding cash, and management is non-committal on near-term catalysts. The market's day-1 decline and FII exodus suggest skepticism is warranted. A hold, not a buy, until the company demonstrates that Poultry momentum translates to consolidated revenue growth and that Animal Healthcare recovery is more than a quarterly deferral.

The adjusted PAT is the number that matters. Track it closely.

Informational and educational content only. Not investment advice.

HESTER BIOSCIENCES LTD. (HESTERBIO) Q1 FY27 Results, Transcript & Analysis — StockWatch